To further assess the relative efficacy of PepE and DMAPE, we performed a side-by-side comparison study with the standard anti-AML chemotherapy drug Ara-C on CD34+ AML or NBM (including hBMSCs) cells. This evidence concerns the gene CD34 and acute myeloid leukemia.